Entity usage

Showing below up to 50 results in range #1 to #50.

1. A stochastically curtailed single‐arm phase II trial design for binary outcomes: Label: en
2. Power and Sample Size Determination in Clinical Trials with Multiple Primary Continuous Correlated Endpoints: Label: en
3. Simultaneous Generation of Binary and Normal Data with Specified Marginal and Association Structures: Label: en
4. Concurrent Generation of Ordinal and Normal Data: Label: en
5. A causal modelling framework for reference-based imputation and tipping point analysis in clinical trials with quantitative outcome: Label: en
6. Analysis of Longitudinal Trials with Protocol Deviation: A Framework for Relevant, Accessible Assumptions, and Inference via Multiple Imputation: Label: en
7. Influence Analysis for the Area Under the Receiver Operating Characteristic Curve: Label: en
8. Not Too Big, Not Too Small: A Goldilocks Approach To Sample Size Selection: Label: en
9. On Using the Bootstrap for Multiple Comparisons: Label: en
10. Precise and accurate power of the rank-sum test for a continuous outcome: Label: en
11. Multivariate Equivalence Tests for Use in Pharmaceutical Development: Label: en
12. Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents: Label: en
13. Incorporation of stochastic engineering models as prior information in Bayesian medical device trials: Label: en
14. Propensity score-integrated composite likelihood approach for augmenting the control arm of a randomized controlled trial by incorporating real-world data: Label: en
15. Propensity score-integrated composite likelihood approach for incorporating real-world evidence in single-arm clinical studies: Label: en
16. Propensity score-integrated power prior approach for incorporating real-world evidence in single-arm clinical studies: Label: en
17. Group sequential design for historical control trials using error spending functions: Label: en
18. Hypoglycemic events analysis via recurrent time-to-event (HEART) models: Label: en
19. Adaptive Allocation for Binary Outcomes Using Decreasingly Informative Priors: Label: en
20. Evidence inconsistency degrees of freedom in Bayesian network meta-analysis: Label: en
21. Mixed-effects models for censored data with autoregressive errors: Label: en
22. Flexible parametric accelerated failure time model: Label: en
23. Alternative Views On Setting Clinical Trial Futility Criteria: Label: en
24. Assessing the prediction accuracy of a cure model for censored survival data with long-term survivors: Application to breast cancer data: Label: en
25. Evaluation of parametric and nonparametric two one-sided tests procedures for assessing bioequivalence of average bioavailability: Label: en
26. On analysis of epidemiological data involving a 2×2 contingency table: an overview of fisher's exact test and yates' correction for continuity: Label: en
27. Effect of Within-Household Reinfestation on Design Sensitivity: Label: en
28. A Longitudinal Approach for Constructing β-Expectation Tolerance Intervals: Label: en
29. Analyzing Randomized Dose Finding Studies with a Primary and a Secondary Endpoint: Label: en
30. Using a Serial Marker to Predict a Repeated Measures Outcome in a Cohort Study: Label: en
31. Bivariate Longitudinal Model For The Analysis Of The Evolution Of Hiv Rna And Cd4 Cell Count In Hiv Infection Taking Into Account Left Censoring Of Hiv Rna Measures: Label: en
32. Analysis of Survival Data with Missing Measurements of a Time-Dependent Binary Covariate: Label: en
33. Chi-Square Test for R×CContingency Tables with Clustered Data: Label: en
34. Assessing the Impact of Endpoint Shopping on Power in Confirmatory Clinical Trials: Label: en
35. Further Developments of the Fisher Information Matrix in Nonlinear Mixed Effects Models with Evaluation in Population Pharmacokinetics: Label: en
36. Covariate-Adjusted Reference Intervals for Diagnostic Data: Label: en
37. Assessing Response Profiles from Incomplete Longitudinal Clinical Trial Data Under Regulatory Considerations: Label: en
38. Treatment of Microarray Experiments as Split-Plot Designs: Label: en
39. Statistical Method for Analysis of the Disease Curve in Animals with Experimental Autoimmune Encephalomyelitis: Label: en
40. Using WinBUGS to Fit Nonlinear Mixed Models with an Application to Pharmacokinetic Modelling of Insulin Response to Glucose Challenge in Sheep Exposed Antenatally to Glucocorticoids: Label: en
41. Testing for Interaction in Studies of Noninferiority: Label: en
42. Phase I (or Phase II) Dose-Ranging Clinical Trials: Proposal of a Two-Stage Bayesian Design: Label: en
43. Evaluating the Agreement of Two Quantitative Assays with Repeated Measurements: Label: en
44. Normalization Methods for Analysis of Microarray Gene-Expression Data: Label: en
45. Examining Outlying Subjects and Outlying Records in Bioequivalence Trials: Label: en
46. Statistical Issues On Objective, Design, And Analysis Of Noninferiority Active-controlled Clinical Trial: Label: en
47. Dunnett's Many-to-One Test and Least Square Means: Label: en
48. Interval Estimation for Weibull-Distributed Life Data Under Type II Progressive Censoring with Random Removals: Label: en
49. Sample size determination for controlling the upper confidence limit of incidence rate of a binomial endpoint: Label: en
50. Approximately optimal designs for phase II clinical studies: Label: en